Elucidating the Role of Pro-renin Receptors in Pancreatic Ductal Adenocarcinoma Progression: A Novel Therapeutic Target in Cancer Therapy.
Mohsen AliakbarianGordon A FernsMahmoud Mohamadzadeh ShabestariAmir Mahmoud AhmadzadehAref AbdollahzadeHoda RahimiRozita KhodashahiMohammad-Hassan ArjmandPublished in: Current cancer drug targets (2024)
Pancreatic cancer is a highly aggressive malignancy with a very poor prognosis. The 5- year survival in these patients is very low, and most patients develop drug resistance to current therapies, so additional studies are needed to identify the potential role of new drug targets for the treatment of pancreatic cancer. Recent investigations have been performed regarding the roles of pro-renin receptors (PRR) in the initiation and development of cancers. PRR is a component of the local renin-angiotensin system (RAS). Local tissue RAS has been known in diverse organ systems, including the pancreas. Various investigations have implicated that PRRs are associated with the upregulation of various signaling pathways, like the renin-angiotensin system pathway, PI3K/Akt/mTOR, and the Wnt-signaling pathways, to contribute to pathological conditions, including cancer. In this review, we presented an overview of the role of PRR in the progression of pancreatic adenocarcinoma.
Keyphrases
- poor prognosis
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- cancer therapy
- prognostic factors
- cell proliferation
- peritoneal dialysis
- drug delivery
- oxidative stress
- pi k akt
- papillary thyroid
- angiotensin converting enzyme
- endoplasmic reticulum stress
- lymph node metastasis
- angiotensin ii
- drug induced